Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19
- PMID: 33007381
- PMCID: PMC7525325
- DOI: 10.1016/j.annonc.2020.09.014
Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19
Conflict of interest statement
Disclosure The authors have declared no conflicts of interest.
Figures
Comment on
-
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).Ann Oncol. 2020 Aug;31(8):1040-1045. doi: 10.1016/j.annonc.2020.04.479. Epub 2020 May 6. Ann Oncol. 2020. PMID: 32387456 Free PMC article.
References
-
- O'Farrell S., Garmo H., Holmberg L., Adolfsson J., Stattin P., Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33:1243–1251. 1243-1251. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
